

## ICR CONFERENCE 2023 PRESENTATION

AARON MILES CHIEF INVESTMENT OFFICER

> (CSE:VRNO) (OTCQX:VRNOF)

Website: verano.com Contact: investors@verano.com

## **BEFORE WE BEGIN**

#### Forward-Looking Information

This presentation contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control.

Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved". The forward-looking information and forward-looking statements contained herein include, but are not limited to statements or information with respect to the Company's position in the marketplace, the proposed completion or buildout of Company facilities, the Company's cultivation capacity, the completion of pending acquisitions, the accretive nature of acquisitions, the fortification of the Company's presence in core markets, the possibility of material organic expansion, delivery of shareholder value and the ability to maintain industry-leading margins and add depth to leadership.

Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein, including, without limitation, the risk factors discussed in the Company's filings on EDGAR at www.sec.com/edgar. The forward-looking information and forward-looking statements contained in this presentation are made as of the date of this presentation, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.

## **BEFORE WE BEGIN**

#### Non-GAAP Financial Measures

This presentation refers to certain non-GAAP measures to evaluate the performance of the Company. The terms "EBITDA", "Adjusted EBITDA" and "Free Cash Flow" do not have any standardized meaning prescribed within International Financial Reporting Standards ("GAAP") and therefore may not be comparable to similar measures presented by other companies.

Such measures should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP. EBITDA is calculated herein as net earnings from operations before interest expense, tax expense, depreciation, and amortization. The Company presents Adjusted EBITDA on a consistent basis from period to period and gains and losses from one-time non-recurring events are eliminated. Adjusted EBITDA is calculated herein as EBITDA adjusted for one-time expenses related to other expenses, gain from investment in associates and acquisition related costs. Free Cash Flow is calculated herein as Cash Flow from Operations minus Capital Expenditures. Management believes that these non-GAAP financial measures provide useful information to readers as a supplement to reported GAAP financial information. Management reviews these non-GAAP financial measures on a regular basis and uses them to evaluate and manage the performance of the Company's operations. These measures should be evaluated only in conjunction with the Company's comparable GAAP financial measures.

## THE US CANNABIS MARKET






## STRONG PROJECTED GROWTH FOR US CANNABIS

#### POTENTIAL GROWTH DRIVERS INCLUDE

- Additional states adopting medical programs
  and/or approval of adult-use legislation
- Continued development of state specific programs
- New and expanded adoption of cannabis by consumers
- Transitioning illicit markets to legal
- Potential utilization of cannabis in synergistic industries



VERANO.<sup>1</sup> Estimates from BDSA.

#### LACK OF FEDERAL MOVEMENT OVERSHADOWS POTENTIONAL GROWTH CATALYSTS



- Amendments to the Controlled Substance Act being evaluated by regulators – i.e. SAFE ACT
- Rescheduling of cannabis under contemplation
- Federal illegality of the industry restricts access to capital and ability to publicly list stock in the US leads to higher priced debt and forces security listing in Canada
- Limited institutional participation and potential inclusion in major indexes anticipated driver of depressed multiples
- 280E tax impact remains
- State-specific operations, each with their own regulations limits potential benefit of economies of scale

## LEGISLATIVE MOMENTUM

#### Encouraged by Biden's Directive

On October 6, 2022, the White House issued a pardon for simple cannabis possession along with the request that the Attorney General and HHS reevaluate cannabis' Schedule 1 drug classification

- Do not anticipate a scheduling decision in the shortterm but encouraged by any progress
- Continuing our work to ensure we are well positioned for the possibility of entering the US capital markets
- In the interim, we will do what we do best: keep our heads down and efficiently operate the business

## WHAT SETS VERANO APART









#### **VERANO**...

## **OUR FOOTPRINT**



## VERANO POISED TO CAPITALIZE ON GROWTH DRIVERS

#### STRATEGIC PORTFOLIO DRIVERS

- Premium and expansive product lines targeting variety of consumer needs
  - Flower, edibles, topicals, and more
- Scaled operations in five potential adult-use markets
  - CT starting on 1/10/23. Maryland approved adult use and is anticipated to begin sales in 2023
- Expanding presence in medical markets viewed as likely nearterm adult-use markets
- Vertical integration increasing margins
  - Vertical in 11 of 13 markets providing wholesale and retail revenue streams
- Balanced approach reduces over-reliance on any single wholesaler or retailer





## REMAINING SELECTIVELY ACQUISITIVE

- Will evaluate opportunities to strategically expand our footprint
- Goal of avoiding significant equity dilution
- Evaluating opportunities thoughtfully and carefully given challenging economic and industry headwinds

## **HOUSE OF BRANDS**







## EXPANDING RETAIL PRESENCE



Zen Leaf<sup>™</sup> aspires to be the most influential cannabis retail brand, and to command brand loyalty of the high-end cannabis consumer. Inspiring our customers drives our mission to capture people's imaginations, satisfy deep and important life needs, and offer unparalleled innovative products underpinning our economic success and cultural influence in an increasingly crowded marketplace.

- Custom store designs provide an edge in the market and create an environment that satisfies the myriad of patron needs through reliability, accessibility, and authenticity
- Superior customer service
- Aggressive expansion underway with existing states and across our broader license footprint



- Locations in Florida and Arizona, two high-growth states
- 62 operational retail locations in Florida
- State-of-the-art dispensaries offering an extensive selection of award-winning products

- One of the widest selections of concentrates for patients needing macro-dosing options
- Won five Best of Arizona medical cannabis awards
- Knowledgeable and friendly staff dedicated to helping medical patients

## FINANCIAL HIGHLIGHTS





## **3Q22 SEQUENTIAL GROWTH**

**\$228 million in revenue representing 2% growth quarter over quarter**, 10% growth year over year

• Driven by strength from New Jersey adult-use sales

#### Adjusted EBITDA margin of 36%

- \$82 million versus \$76 million in the prior quarter
- Driven by reduced SG&A expense due to decreased earnout expense in addition to headcount reduction and store hour rationalization



## **FINANCIAL RESULTS**

- Retail / wholesale revenue split of 70% / 30% for the third quarter<sup>1</sup>
- \$23 million of 3Q22 CAPEX fully funded by operating cash flow
  - Expecting ~\$25-50 million of capex in FY23
- SG&A expenses for the third quarter were 38% of revenues, a ~700+ bps decrease from the second quarter's 45% of revenues

\$USD thousands	Third Quarter 2022 Results
Revenue	\$227,588
Gross Profit	\$122,994
Income from Operations	\$37,075
Net Loss	\$(42,993)


## A TOP COMPETITOR WITH STRONG GROWTH

• Top five MSO by revenue

VERANO.

- Experiencing rapid growth (organically and through M&A)
- Our scale allows for operational efficiencies, more profitable cultivation and the ability to quickly adapt to changing legislation

### THE CANNABIS INDUSTRY'S LEADING EBITDA PROFILE



#### <sup>1</sup>Peer set includes the largest MSOs by revenue.

## CAPITAL ALLOCATION





## FINANCIAL FLEXIBILITY

\$USD thousands	As of September 30, 2022
Cash	\$76,418
Total Assets	\$2,623,027
Debt	\$392,135
Total Liabilities	\$1,082,733



## STRONG CASH MANAGEMENT

Taking measures that we believe will insulate and prepare the business for a potential recessionary environment by prioritizing cash flow.

- Delayed capex we do not believe will provide returns in the immediate term
- Will react accordingly as progression towards adult-use picks up in certain markets
- Targeting \$20m capex in 4Q and \$25-50m in 2023



## REFINANCED CREDIT FACILITY AND ADDED FLEXIBLE TERMS

#### Extended maturity

\$350 million facility refinanced at an initial rate of 12.75%<sup>1</sup> in a rising interest rate environment, with maturation in October 2026 and up to \$270 million in upsize optionality<sup>2</sup>


#### Prepayment option

Option to prepay up to \$100 million for a \$1 million prepayment penalty fee Expect to leverage unencumbered real estate

Goal of bringing down blended cost of capital to 10.5% in the medium term



## WHAT SETS VERANO APART



#### **VERANO**...

# VERANO, ICR CONFERENCE 2023 PRESENTATION

#### THANK YOU

(CSE:VRNO) (OTCQX:VRNOF)

Website: verano.com Contact: investors@verano.com